Page 559 - Read Online

Bieu et al. Hepatoma Res 2020;6:49 I http://dx.doi.org/10.20517/2394-5079.2020.39 Page 9 of 10

In conclusion, Via this case report and review of literature, we suppose that bridging therapy combining
SBRT and TACE may be most beneficial over TACE alone in HCC patients with a high risk of drop-
out from WL for LT. It is necessary to perform a randomized trial to provide more evidence to guide the
treatment options for these patients.

DECLARATIONS
Acknowledgments
We acknowledge our patient for providing informed consent for this case report.

Authors’ contributions
Made substantial contributions to conception and design of the case report and performed data analysis
and interpretation: Bieu BQ
Performed data acquisition, as well as providing administrative, technical, and material support: Chau ND,
Kien NX, Thanh LV, Quang VV, Ky TD, Thinh NT, Bang MH
Read and approved the final manuscript: Bieu BQ, Chau ND, Kien NX, Thanh LV, Quang VV, Ky TD,
Thinh NT, Bang MH

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Obtain the informed consent from patient.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. IARC. Cancer Today. Available from: http://gco.iarc.fr/today/. [Last accessed on 24 Jul 2020]
2. Coletta M, Nicolini D, Benedetti Cacciaguerra A, Mazzocato S, Rossi R, et al. Bridging patients with hepatocellular cancer waiting for
liver transplant: all the patients are the same? Transl Gastroenterol Hepatol 2017;2:78.
3. Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on
transplantability and recurrence rate. J Hepatol 2013;58:609-18.
4. Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant
allocation system. Am J Transplant 2010;10:1643-8.
5. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival
according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-83.
6. Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, et al. A follow-up analysis of the pattern and predictors of dropout from the
waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver
Transpl 2003;9:684-92.
7. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, et al. Response to preoperative chemoembolization correlates with
outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007;13:272-9.
8. Otto G, Herber S, Heise M, Lohse AW, Mönch C, et al. Response to transarterial chemoembolization as a biological selection criterion for